Article
Angiotensin-converting enzyme gene polymorphism determines the antiproteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease. Austrian Study Group of the Effects of Enalapril Treatment in Proteinuric Renal Disease.
Kidney & blood pressure research - 1 Jan 1998
Haas M, Yilmaz N, Schmidt A, Neyer U, Arneitz K, Stummvoll H K, Wallner M, Auinger M, Arias I, Schneider B, Mayer G
Abstract excerpt
Angiotensin-converting enzyme (ACE) inhibitors are known to reduce blood pressure and proteinuria in a variety of different glomerular diseases. Nonetheless, a marked interindividual difference in the efficacy of these agents exists. The activity of the ACE and therefore of the renin-angiotensin-...
Topics
- Adult
- Angiotensin-Converting Enzyme Inhibitors
- Creatinine
- DNA
- Enalapril
- Female
- Follow-Up Studies
- Genotype
- Hemodynamics
- Humans
- Male
- Middle Aged
- Peptidyl-Dipeptidase A
- Polymerase Chain Reaction